{"DataElement":{"publicId":"7072150","version":"1","preferredName":"Oral Route of Administration Contrast Agent Administered Type","preferredDefinition":"The type of oral contrast agent administered either positive or negative as part of an imaging procedure.","longName":"AGSCAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"7071865","version":"1","preferredName":"Procedure Agents Domain Oral Route of Administration Contrast Agent Administered","preferredDefinition":"A domain utilized for the submission of information encompassing and representing data, vocabulary or records related to agents used as part of a procedure._The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins._Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue._The act of having given something (e.g., a medication or test).","longName":"6663252v1.0:7071863v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6663252","version":"1","preferredName":"Procedure Agents Domain","preferredDefinition":"A domain utilized for the submission of information encompassing and representing data, vocabulary or records related to agents used as part of a procedure.","longName":"C117755","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procedure Agents Domain","conceptCode":"C117755","definition":"A domain utilized for the submission of information encompassing and representing data, vocabulary or records related to agents used as part of a procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8394B60A-D64E-39C1-E053-F662850A000B","latestVersionIndicator":"Yes","beginDate":"2019-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-08","modifiedBy":"ONEDATA","dateModified":"2019-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7071863","version":"1","preferredName":"Oral Route of Administration Contrast Agent Administered","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.:Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue.:The act of having given something (e.g., a medication or test).","longName":"C38288:C390:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Contrast Agent","conceptCode":"C390","definition":"Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"990119E2-974F-4A59-E053-F662850ADEF0","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-05","modifiedBy":"ONEDATA","dateModified":"2019-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"990119E2-9760-4A59-E053-F662850ADEF0","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-05","modifiedBy":"KUMMEROA","dateModified":"2020-06-11","changeDescription":"Released. AK 2020-6-11 Created for CDSIC aligned NCI Standard CRFs. ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2717683","version":"1.1","preferredName":"Oral Contrast Agent Type","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins._Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue._Something distinguishable as an identifiable class based on common qualities.","longName":"ORAL_CONTRAST_TP","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"0","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Negative","valueDescription":"Negative Contrast Agent","ValueMeaning":{"publicId":"2717684","version":"1","preferredName":"Negative Contrast Agent","longName":"2717684","preferredDefinition":"Contrast media that has a lower amplification and intensity than the surrounding tissue making the contrast look less opaque when seen in an x-ray.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negative Contrast Agent","conceptCode":"C71960","definition":"Contrast media that has a lower amplification and intensity than the surrounding tissue making the contrast look less opaque when seen in an x-ray.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"428B61E4-2CDF-1694-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CHILLIJ","dateCreated":"2007-12-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBA87A7-535C-3649-E053-F662850A6B71","beginDate":"2008-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Positive","valueDescription":"Positive Contrast Agent","ValueMeaning":{"publicId":"2717685","version":"1","preferredName":"Positive Contrast Agent","longName":"2717685","preferredDefinition":"Contrast media that has a higher amplification and intensity than the surrounding tissue making the contrast look more opaque when seen in an x-ray.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positive Contrast Agent","conceptCode":"C71959","definition":"Contrast media that has a higher amplification and intensity than the surrounding tissue making the contrast look more opaque when seen in an x-ray.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"428B61E4-2D04-1694-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CHILLIJ","dateCreated":"2007-12-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBA87A7-5348-3649-E053-F662850A6B71","beginDate":"2008-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2717682","version":"1","preferredName":"Oral Route of Administration Contrast Agent Type","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.:Substances used in radiography that allow visualization of certain tissues.:Type; a subdivision of a particular kind of thing.","longName":"C38288:C390:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Contrast Agent","conceptCode":"C390","definition":"Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"428B61C1-2FE4-15B5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-30","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2007-12-30","modifiedBy":"ONEDATA","dateModified":"2007-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"4FBA87A7-52E5-3649-E053-F662850A6B71","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-05-17","modifiedBy":"KNABLEJ","dateModified":"2017-07-07","changeDescription":"7/7/17 jk transferred context and added registration status per Round 5 finalization task.  5/17/17 tt, VD versioned to 1.1. Changed coded PVs to text, min/max length, definition, Context, registration status and added to NCI Standards CSI per Rnd 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6921971","version":"1","longName":"CDISC Aligned Collection CDEs","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"7318324","version":"1","longName":"CT Image - CDISC Aligned ","context":"NCI Standards"},{"publicId":"7318326","version":"1","longName":"CT Image Agent - CDISC Aligned","context":"NCI Standards"}]},{"publicId":"7434158","version":"1","longName":"CTEP CDISC Harmonization","context":"CTEP","ClassificationSchemeItems":[{"publicId":"7590126","version":"1","longName":"CTEP CDISC CT Imaging Agent","context":"CTEP"}]}],"AlternateNames":[{"name":"AG_AGCAT_ORAL","type":"CTEP CDISC CDE","context":"CTEP"}],"ReferenceDocuments":[{"name":"If oral contrast was used, sp","type":"Preferred Question Text","description":"If oral contrast was used, specify type","url":null,"context":"NCI Standards"},{"name":"CDISC Aligned NCI Standard Equivalent CDE","type":"CDISC Note","description":"This data element is to be used for CDISC aligned data collection in place of CDE 2726095 from the original NCI Standard CRF Template.","url":null,"context":"NCI Standards"},{"name":"CTEP Text1","type":"Alternate Question Text","description":"Specify oral contrast type","url":null,"context":"CTEP"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"99100481-4447-0333-E053-F662850A090C","latestVersionIndicator":"Yes","beginDate":"2019-12-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-06","modifiedBy":"GDEEN","dateModified":"2023-02-13","changeDescription":"Created for CDISC aligned NCI Standard CRF task. ghd","administrativeNotes":"02.13.23_Set Reg Status to Standard for all CDISC Aligned content_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}